Uses of Kepivance

Kepivance is a prescription medication used to treat the symptoms of oral mucositis. Kepivance can be used as a single dose or in combination with other medications.
Kepivance belongs to a class of drugs known as chemoprotective agents, keratinocyte growth factors. Currently, researchers have not confirmed whether Kepivance is safe and effective in children younger than 1 year of age.
Kepivance (palifermin) is a truncated human KGF generated by recombinant DNA technology in E coli. Kepivance is a water-soluble 140 amino acid protein with a molecular weight of 16.3 kilodaltons. It differs from endogenous human KGF in that the first 23 N-terminal amino acids have been deleted to improve protein stability.
Kepivance is supplied as a sterile, white, preservative-free lyophilized powder for intravenous injection after reconstitution with 1.2 mL Sterile Water for Injection, USP. The reconstitution yielded a clear, colorless (5 mg/mL) Kepivance solution with a pH of 6.5. Each single dose vial of Kepivance contains palifermin (6.25 mg), with L histidine (1.94 mg), mannitol (50 mg), polysorbate 20 (0.13 mg or 0.01% w/v) and sucrose (25). mg).

Kepivance is indicated in the following cases:
Kepivance is indicated for the reduction of frequency and duration of severe oral mucositis in patients with hematologic malignancies who are receiving chemotherapeutic myelotoxicity in autologous hematopoietic stem cell-supported medium. Kepivance is indicated as supportive care for preparative regimens that are expected to cause WHO grade 3 mucositis in the majority of patients. Kepivance is used in people receiving chemotherapy to treat blood cancers (Hodgkin's disease, multiple myeloma, leukemia). This medicine is not a treatment for cancer.

The safety and efficacy of Kepivance have not been established in patients with non-hematological malignancies.
Kepivance was not effective in reducing the incidence of severe mucositis in patients with hematological malignancies receiving myelotoxic therapy in the hematopoietic stem cell-supported environment.
Kepivance is not recommended for use with melphalan 200 mg/m2 as a treatment regimen.

The recommended dose of Kepivance is 60 mcg/kg/day, administered as an intravenous injection for 3 consecutive days before and 3 consecutive days after myelosuppression, for a total of 6 doses. Administer the first 3 doses prior to myelotoxicity. Administer the third dose 24 to 48 hours prior to initiation of myelotoxic therapy. Administer the last 3 doses after myelosuppression is complete; Administer the first dose on the day of the hematopoietic stem cell infusion following completion of the infusion, and for at least 7 days after the most recent Kepivance administration.

Kepivance can cause serious side effects including:
Allergy, rash, hives, Difficulty breathing, Swelling of face, lips, tongue or throat Blurred vision, Itching, Eye pain, Seeing halos bright or dazzling around a light source when viewed. When experiencing the above symptoms, it is necessary to quickly call a doctor for advice and timely treatment.
The most common side effects seen from taking Kepivance include:
Fever, Swelling or redness of your skin, Itching, Rash, Abnormal blood tests.

Kepivance is supplied as a lyophilized powder in a single dose vial containing 6.25 mg palifermin. Kepivance vials are available at:
One pack of 3 vials (NDC 66658-112-03) One pack of 6 vials (NDC 66658-112-06) Store Kepivance vials in the distribution pack in your carton. it is cooled at 2°C to 8°C until used. Avoid direct light.
Before injection, allow Kepivance to reach room temperature for up to 1 hour, protected from light. Leave Kepivance at room temperature for more than 1 hour.

For pregnant women
Based on findings in animal studies, Kepivance may cause fetal harm when administered to a pregnant woman. There are no data available on the use of Kepivance in pregnant women to inform the risk of major birth defects and drug-related miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, intravenous administration of palifermin to pregnant rabbits and rats during organogenesis resulted in embryonic death and developmental changes.
All pregnancies carry an underlying risk of birth defects, pregnancy loss, or other adverse outcomes. In the United States population, the estimated baseline risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
For lactating women There are no data on the presence of Kepivance in breast milk, effects on the nursing infant or on milk production. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in a nursing infant, breastfeeding should be discontinued during treatment and for at least 2 weeks after the last dose.
For women and men about fertility Based on findings from animal studies, the ingredient palifermin in Kepivance may decrease fertility in women and men in terms of fertility. born.
In a nutshell, Kepivance is a man-made form of a protein that affects the growth of cells in the tissues lining the mouth and digestive tract. Kepivance is used to prevent or heal mouth sores and ulcers in patients receiving chemotherapy and stem cell therapy.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.

Reference source: rxlist.com